TENAX THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
TENAX THERAPEUTICS, INC. (TENX) reported Increase (Decrease) in Accrued Liabilities of $163.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-07-31
- TENAX THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$862.00K, a 183.20% decline year-over-year.
- TENAX THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $1.02M.
- TENAX THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $124.00K, a 77.74% decline year-over-year.
- TENAX THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$974.00K, a 352.99% decline year-over-year.
- TENAX THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was -$421.00K, a 180.50% decline from fiscal 2024.
- TENAX THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $523.00K, a 120.68% increase from fiscal 2023.
- TENAX THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $237.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$862.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $163.00K 10-Q · filed 2026-07-31 | $287.00K derived: sum of 3 quarters · filed 2026-07-31 | -$687.00K derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $1.02M 10-Q · filed 2026-05-12 | $1.15M derived: sum of 2 quarters · filed 2026-05-12 | $175.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.21M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$850.00K derived: sum of 2 quarters · filed 2026-03-10 | $186.00K derived: sum of 3 quarters · filed 2026-07-31 | -$421.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | -$974.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $62.00K derived: sum of 2 quarters · filed 2026-07-31 | -$545.00K 10-Q · filed 2025-11-12 | $12.00K derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $429.00K 10-Q · filed 2026-07-31 | $986.00K derived: sum of 3 quarters · filed 2026-07-31 | $1.37M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | -$607.00K 10-Q · filed 2026-05-12 | -$50.00K derived: sum of 2 quarters · filed 2026-05-12 | $335.00K derived: sum of 3 quarters · filed 2026-05-12 | $392.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $557.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $942.00K derived: sum of 2 quarters · filed 2026-03-10 | $999.00K derived: sum of 3 quarters · filed 2026-03-10 | $523.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $385.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $442.00K derived: sum of 2 quarters · filed 2025-11-12 | -$34.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$419.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$476.00K 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $237.00K 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |